Shares of Wave Life Sciences Ltd. (WVE) gained nearly 4% on Wednesday morning after announcing positive data from the Phase 2 Forward-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
WVE is currently trading at $9.80, up $0.36 or 3.81%, on the Nasdaq. The stock opened its trading at $10.82 after closing Tuesday at $9.44. The stock has traded between $4.25 and $16.74 in the past 52-week period.
FORWARD-53 achieved all trial goals, demonstrating sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing. WVE-N531 continues to be safe and well-tolerated.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.